Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Change in Acquisitions & Divestments (2022 - 2025)

Rani Therapeutics Holdings (RANI) has 4 years of Change in Acquisitions & Divestments data on record, last reported at $5.8 million in Q2 2025.

  • For Q2 2025, Change in Acquisitions & Divestments fell 68.41% year-over-year to $5.8 million; the TTM value through Sep 2025 reached $47.0 million, down 41.26%, while the annual FY2024 figure was $77.6 million, 25.68% down from the prior year.
  • Change in Acquisitions & Divestments reached $5.8 million in Q2 2025 per RANI's latest filing, down from $21.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $35.0 million in Q2 2023 and bottomed at $3.0 million in Q4 2022.
  • Average Change in Acquisitions & Divestments over 4 years is $19.2 million, with a median of $20.3 million recorded in 2024.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 661.67% in 2023, then tumbled 68.41% in 2025.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $3.0 million in 2022, then soared by 661.67% to $22.8 million in 2023, then decreased by 11.16% to $20.3 million in 2024, then tumbled by 71.67% to $5.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $5.8 million in Q2 2025, $21.0 million in Q1 2025, and $20.3 million in Q4 2024.